0.9228
1.13%
+0.0103
After Hours:
.9399
0.0171
+1.85%
Bluebird bio Inc stock is currently priced at $0.9228, with a 24-hour trading volume of 5.13M.
It has seen a +1.13% increased in the last 24 hours and a -23.10% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.9079 pivot point. If it approaches the $0.9346 resistance level, significant changes may occur.
Previous Close:
$0.9125
Open:
$0.9102
24h Volume:
5.13M
Market Cap:
$177.86M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-0.9047
EPS:
-1.02
Net Cash Flow:
$-286.43M
1W Performance:
-9.53%
1M Performance:
-23.10%
6M Performance:
-69.84%
1Y Performance:
-74.92%
Bluebird bio Inc Stock (BLUE) Company Profile
Name
Bluebird bio Inc
Sector
Industry
Phone
339-499-9300
Address
60 Binney Street, Cambridge, MA
Bluebird bio Inc Stock (BLUE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-28-23 | Initiated | JP Morgan | Overweight |
Mar-07-23 | Initiated | Robert W. Baird | Outperform |
Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
Nov-08-21 | Reiterated | Barclays | Equal Weight |
Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
Nov-08-21 | Reiterated | Wedbush | Neutral |
Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Aug-10-21 | Resumed | William Blair | Mkt Perform |
Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
Nov-11-20 | Initiated | Berenberg | Buy |
Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
Nov-05-20 | Downgrade | Stifel | Buy → Hold |
Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
Oct-20-20 | Initiated | Mizuho | Buy |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
Mar-27-20 | Upgrade | Stifel | Hold → Buy |
Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Feb-03-20 | Resumed | BofA/Merrill | Buy |
Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
Oct-01-19 | Initiated | Stifel | Hold |
Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird bio Inc Stock (BLUE) Latest News
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
Zacks Investment Research
Is Bluebird Bio Stock a Buy?
The Motley Fool
Better Buy: Bluebird Bio Vs. Novavax
The Motley Fool
Is This Beaten-Down Stock a Good Acquisition Target?
The Motley Fool
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
The Motley Fool
Bluebird bio Inc Stock (BLUE) Financials Data
Bluebird bio Inc (BLUE) Revenue 2024
BLUE reported a revenue (TTM) of $21.73 million for the quarter ending September 30, 2023, a +322.60% rise year-over-year.
Bluebird bio Inc (BLUE) Net Income 2024
BLUE net income (TTM) was -$91.17 million for the quarter ending September 30, 2023, a +79.91% increase year-over-year.
Bluebird bio Inc (BLUE) Cash Flow 2024
BLUE recorded a free cash flow (TTM) of -$286.43 million for the quarter ending September 30, 2023, a +35.86% increase year-over-year.
Bluebird bio Inc (BLUE) Earnings per Share 2024
BLUE earnings per share (TTM) was -$0.74 for the quarter ending September 30, 2023, a +87.87% growth year-over-year.
About Bluebird bio Inc
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy; and Gritstone Oncology, Inc. to research, develop, and commercialize products for the treatment of cancer using cell therapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):